Prelude Therapeutics Incorporated
PRLD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $45 | $42 | $70 |
| - Cash | $48 | $26 | $40 | $12 |
| + Debt | $15 | $18 | $18 | $18 |
| Enterprise Value | – | $37 | $20 | $75 |
| Revenue | $7 | $0 | $0 | $4 |
| % Growth | – | – | -100% | – |
| Gross Profit | $6 | $0 | $0 | $4 |
| % Margin | 93.5% | – | – | 100% |
| EBITDA | -$19 | -$32 | -$34 | -$33 |
| % Margin | -296.9% | – | – | -833.6% |
| Net Income | -$20 | -$31 | -$32 | -$29 |
| % Margin | -303.5% | – | – | -718.3% |
| EPS Diluted | -0.26 | -0.41 | -0.42 | -0.38 |
| % Growth | 36.6% | 2.4% | -10.5% | – |
| Operating Cash Flow | -$19 | -$26 | -$34 | -$21 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$19 | -$26 | -$34 | -$21 |